NASDAQ:APLM Apollomics (APLM) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free APLM Stock Alerts $0.45 -0.02 (-4.26%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.43▼$0.4950-Day Range$0.45▼$0.7752-Week Range$0.40▼$6.45Volume245,270 shsAverage Volume183,745 shsMarket Capitalization$40.27 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Apollomics alerts: Email Address Apollomics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,011.1% Upside$5.00 Price TargetShort InterestHealthy0.32% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.32 out of 5 starsMedical Sector725th out of 916 stocksPharmaceutical Preparations Industry330th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingApollomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageApollomics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.32% of the float of Apollomics has been sold short.Short Interest Ratio / Days to CoverApollomics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Apollomics has recently increased by 34.95%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldApollomics does not currently pay a dividend.Dividend GrowthApollomics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APLM. Previous Next 0.8 News and Social Media Coverage News SentimentApollomics has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Apollomics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for APLM on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Apollomics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apollomics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 19.13% of the stock of Apollomics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioApollomics has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Apollomics Stock (NASDAQ:APLM)Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.Read More APLM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APLM Stock News HeadlinesApril 25, 2024 | globenewswire.comApollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneApril 17, 2024 | msn.comApollomics (APLM) Price Target Decreased by 58.93% to 5.87April 28, 2024 | WealthPress (Ad)Massive breakthrough for options traders.A 34 year old man from central florida has uncovered a totally new way to trade options… Already this year it’s allowed real people to capture top returns of 50%... 100%... Even 200% overnight… Without using technical patterns, momentum, A.I. or any of the other commonly used strategies… Now, it’s important to mention that nothing is 100% perfect in terms of trading. April 16, 2024 | finance.yahoo.comApollomics, Inc. (APLM) Interactive Stock Chart - Yahoo FinanceApril 10, 2024 | globenewswire.comApollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingApril 2, 2024 | finance.yahoo.comApollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 28, 2024 | msn.comApollomics GAAP EPS of -$2.32March 28, 2024 | globenewswire.comApollomics Highlights Clinical Progress and Reports Full Year 2023 Financial ResultsApril 28, 2024 | WealthPress (Ad)Massive breakthrough for options traders.A 34 year old man from central florida has uncovered a totally new way to trade options… Already this year it’s allowed real people to capture top returns of 50%... 100%... Even 200% overnight… Without using technical patterns, momentum, A.I. or any of the other commonly used strategies… Now, it’s important to mention that nothing is 100% perfect in terms of trading. March 4, 2024 | finance.yahoo.comApollomics Names Matthew Plunkett as Chief Financial OfficerMarch 4, 2024 | globenewswire.comApollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial OfficerFebruary 22, 2024 | benzinga.comApollomics Stock (NASDAQ:APLM), Short Interest ReportJanuary 20, 2024 | finanznachrichten.deApollomics Inc.: Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyJanuary 19, 2024 | finance.yahoo.comApollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyJanuary 17, 2024 | stockhouse.comApollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology ConferenceJanuary 3, 2024 | finance.yahoo.comApollomics Completes Patient Enrollment for Phase 3 Trial of Leukemia TreatmentDecember 17, 2023 | morningstar.comApollomics Inc Ordinary Shares - Class A APLMDecember 12, 2023 | morningstar.comApollomics Inc Ordinary Shares - Class ADecember 7, 2023 | finance.yahoo.comApollomics Presents Data from Phase 2 Clinical Trials of Lung Cancer MedicationDecember 4, 2023 | finance.yahoo.comApollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping MutationNovember 28, 2023 | ca.finance.yahoo.comApollomics, Inc. (APLM)November 28, 2023 | finance.yahoo.comApollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)November 16, 2023 | marketwatch.comApollomics Shares More Than Double on Partner's Approval for Commercialization of VebreltinibNovember 16, 2023 | msn.comWhy Is Cancer Firm Apollomics Stock Trading Higher Today?November 16, 2023 | finance.yahoo.comApollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung CancerOctober 31, 2023 | finance.yahoo.comApollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET DysregulationOctober 27, 2023 | msn.comApollomics stock soars 76% following positive report for brain cancer therapySee More Headlines Receive APLM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apollomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/28/2024Next Earnings (Estimated)6/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APLM CUSIPN/A CIK1944885 Webwww.apollomicsinc.com Phone886-2-7713-7952FaxN/AEmployees45Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,011.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.95 Quick Ratio2.95 Sales & Book Value Annual Sales$1.22 million Price / Sales33.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book0.94Miscellaneous Outstanding Shares89,496,000Free FloatN/AMarket Cap$40.27 million OptionableNot Optionable Beta1.30 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Guo-Liang Yu Ph.D. (Age 61)Co-Founder, CEO & Executive Chairman Dr. Sanjeev Redkar MBA (Age 55)Ph.D., Co-Founder, President & Executive Director Dr. Matthew James Plunkett Ph.D. (Age 52)Chief Financial Officer Dr. Kin-Hung Yu M.D. (Age 62)Chief Medical Officer Dr. Chinglin Lai Ph.D.Senior Vice President of Biostatistics & Data ManagementKey CompetitorsNextCureNASDAQ:NXTCCleneNASDAQ:CLNNBolt BiotherapeuticsNASDAQ:BOLTRockwell MedicalNASDAQ:RMTIAadi BioscienceNASDAQ:AADIView All CompetitorsInstitutional OwnershipPowell Investment Advisors LLCBought 130,297 shares on 4/16/2024Ownership: 0.146%View All Institutional Transactions APLM Stock Analysis - Frequently Asked Questions Should I buy or sell Apollomics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apollomics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" APLM shares. View APLM analyst ratings or view top-rated stocks. What is Apollomics' stock price target for 2024? 1 analysts have issued 1-year price targets for Apollomics' stock. Their APLM share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 1,011.1% from the stock's current price. View analysts price targets for APLM or view top-rated stocks among Wall Street analysts. How have APLM shares performed in 2024? Apollomics' stock was trading at $0.9650 at the beginning of the year. Since then, APLM stock has decreased by 53.4% and is now trading at $0.45. View the best growth stocks for 2024 here. Are investors shorting Apollomics? Apollomics saw a increase in short interest in April. As of April 15th, there was short interest totaling 209,300 shares, an increase of 34.9% from the March 31st total of 155,100 shares. Based on an average daily trading volume, of 191,500 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.3% of the shares of the stock are sold short. View Apollomics' Short Interest. When is Apollomics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 27th 2024. View our APLM earnings forecast. What ETFs hold Apollomics' stock? ETFs with the largest weight of Apollomics (NASDAQ:APLM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). Who are Apollomics' major shareholders? Apollomics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Powell Investment Advisors LLC (0.15%). How do I buy shares of Apollomics? Shares of APLM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APLM) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
